Drugs / NKF-INS(G)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06627478 | Oct 2024 → Jul 2025 | — | Xentria, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKF-INS(G) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06627478 ↗ |
| Known as | NKF-INS Glargine (G) | “between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®” NCT06627478 ↗ |
| Route | Subcutaneous | “Single subcutaneous dose of 0.5 IU/kg administered over three periods” NCT06627478 ↗ |